TCT In Brief
This article was originally published in The Gray Sheet
Executive Summary
HORIZONS-AMI: Two-year follow-up results from the 3,000-patient randomized trial show that ischemia-driven target lesion revascularization - the primary endpoint of the study - was 6.8% in patients receiving Boston Scientific's Taxus Express stent compared to 11.6% for those treated with a bare metal stent, firm reports during the Transcatheter Cardiovascular Therapeutics conference in San Francisco. For the secondary endpoint, target vessel revascularization, the rates for the Taxus Express and bare metal stent groups were 8.9% and 13.3%, respectively. The rate of major adverse cardiac events at two years was 11% for the drug-eluting stent and 11.2% for the bare metal stent. HORIZONS-AMI is designed to assess the safety and efficacy of Taxus Express in high-risk acute myocardial infarction patients
You may also be interested in...
Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs
Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.